The early Phase III data appear similar for competing anti-PCSK9 mAbs from Amgen Inc. on one end and partners Regeneron Pharmaceuticals Inc. and Sanofi on the other. But starting mid-year, additional data in the populations where PCSK9 inhibitors are most likely to be used - familial hypercholesterolemia or statin intolerance - should begin to provide a better view on how the mAbs will compete.

Inhibiting proprotein convertase subtilisin/kexin 9 reduces LDL-C by preventing the protein from enhancing the degradation of LDL receptors that clear LDL from the circulation.